CTLA4-Ig gene therapyAlternative Names: AdCTLA4Ig
Latest Information Update: 20 Jul 2006
At a glance
- Originator Nonindustrial source
- Class Gene therapies
- Mechanism of Action Immunosuppressants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Heart transplant rejection; Lung transplant rejection; Rheumatoid arthritis